I. AMENDMENTS

In the claims:

Please amend claims 1 and 3, as follows:

1. (Amended) A process for preparing a biologically active fraction designated ASB03 from a composition of *Scutellariae barbatae* comprising extracting from a filtrate, a fraction soluble in an organic solvent wherein said fraction has an optical absorbance between about 200nm to about 500nm.

2. (Reiterated) The process of claim 1, comprising the steps of:

a) steeping an effective amount of *Scutellariae barbatae* in an effective amount of hot water to obtain a liquid extract;

b) filtering the extract to obtain a filtrate designated ESBa;

c) extracting the filtrate with an effective amount of an organic solvent to obtain ESBb;

d) concentrating the extract; and

e) isolating a fraction having an optical absorbance at about 200 nm to about 450 nm to isolate ASB03.

B1

3. (Amended) The process of claim 1, comprising the steps of:

a) obtaining a ~~supernatant by extracting at least two times with ethanol from a~~ liquid extract of *Scutellariae barbatae* and obtaining a supernatant by extracting the liquid extract at least two times with ethanol;

b) obtaining a concentrated supernatant by extracting the supernatant at least three times with methanol;

c) evaporating the methanol with nitrogen gas;

d) resuspending the extract in about 12 to about 18 ml of water and drying;

e) resuspending the dried extract in a pharmaceutically acceptable carrier to form a solution;

f) running the solution over a C-18 mini-column;

g) washing the column with at least about 35 ml of water;

h) washing the column with at least 15 ml of 25% methanol;

i) evaporating the methanol with nitrogen gas;

j) resuspending the extract in a liquid carrier; and

k) obtaining the active fraction by a C-18 hydrophobic HPLC chromatography to obtain a biologically active extract designated ASB03 having an optical absorbance from about 200 nm to about 500nm.

4. (Reiterated) A biologically active extract obtained by the process of claim 1.

5. (Reiterated) A composition comprising the extract of claim 4 and a pharmaceutically acceptable carrier.

B1 6. (Reiterated) A composition comprising the extract of claim 4 and an anti-angiogenic or immunostimulatory agent.

Claims 7 to 18 and 21 (Withdrawn)

19. (Reiterated) A kit for treating a disorder associated with pathological neovascularization in a host, comprising a therapeutically effective amount of the extract of claim 4 and instructions for use.

20. (Reiterated) The kit of claim 19, wherein the disorder is selected from the group consisting of cancer, arthritic conditions, neovascular-based dermatological conditions, diabetic retinopathy, Karposi's Sarcoma, age-related macular degeneration, restinosis, telangectasia, glaucoma, keloids, corneal graft rejection, wound granularization, angiofibroma, Osler-Webber Syndrome, myocardial angiogenesis, and scleroderma.